Merck & Co., Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Davis
- Full Time Employees
- 73,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 126 East Lincoln Avenue Rahway NJ United States of America 07065
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
Protillion Biosciences Announces Drug Discovery Collaboration with Merck
Merck: Buy The Dip On This Dividend Growth Pharma Leader
3 Dividend Stocks to Hold for the Long Haul
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Merck Animal Health to Acquire TARGAN
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health